Advisory Committee on Medicines Scheduling (ACMS #21)
Summary of delegate's interim decisions
Substance
Interim decision
Sildenafil
The delegate's interim decision is that the current scheduling of sildenafil remains appropriate.
Vardenafil
The delegate's interim decision is that the current scheduling of vardenafil remains appropriate.
Ibuprofen combined with paracetamol
The delegate's interim decision is that the current scheduling of ibuprofen combined with paracetamol remains appropriate.
Esomeprazole
Schedule 4 – Amend Entry
ESOMEPRAZOLE except when included in Schedule 2.
Schedule 3 – Delete Entry
Schedule 2 – Amend Entry
ESOMEPRAZOLE in oral preparations containing 20 mg or less per dosage unit for the relief of heartburn and other symptoms of gastro-oesophageal reflux disease, in packs containing not more than 14 days' supply.
The proposed implementation date is 1 February 2018.
Stiripentol
Appendix K – New Entry
STIRIPENTOL
The proposed implementation date is 1 February 2018.
